Dr. Reddys Laboratories Inc. has secured FDA approval for its ANDA82176 generic version of Qsymia (phentermine and topiramate extended-release), entering a significant weight-management market following manufacturer side effects. This approval creates competitive pressure on brand-name pricing in the $1 billion plus GLP-1 weight trend.